BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

...milestone payment worth up to €300 million upon U.S. approval of the drug.By binding to NTCP...
...and High-Tech Gründerfonds. Founded in 2011, the company is based in Bad Homburg, Germany.TARGETSNTCP (SLC10A1) - Sodium taurocholate cotransporting polypeptide Paul...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New investors in the kidney disease company include...
BioCentury | Nov 1, 2019
Clinical News

Hepatitis D draft guidance outlines surrogate endpoints

...Sarasar lonafarnib, a farnesyl transferase inhibitor from Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR), and Myrcludex bulevirtide, an NTCP...
...Alanine transaminase; HBsAg - Hepatitis B surface antigen; IFNλ - interferon λ; NTCP (SLC10A1) - Sodium taurocholate cotransporting polypeptide Sandi...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | Jun 22, 2019
Financial News

Mirum, Fulcrum file for IPOs

On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New...
BioCentury | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BioCentury | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BioCentury | Aug 3, 2018
Company News

Shire earnings check Takeda's boxes

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same...
BioCentury | Jul 31, 2018
Company News

Shire earnings check Takeda's boxes

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same...
BioCentury | Jan 25, 2018
Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
Items per page:
1 - 10 of 50